Navigation Links
PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
Date:4/21/2010

MADRID, April 21 /PRNewswire/ -- PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

The AACR meeting is the leading convention on cancer research, bringing together more than 17,000 attendees each year and covering breakthroughs in oncology and basic, clinical and epidemiological research.

Two trials provided new data on Yondelis(R) (trabectedin), a marine-based anti-tumor drug currently produced by chemical synthesis. Yondelis(R) (trabectedin) has European Commission approval for advanced and metastatic soft tissue sarcoma (STS) and for recurrent platinum-sensitive ovarian cancer in combination with Doxil/Caelyx.

Various in vitro trials have shown that trabectedin's activity depends at least partly on the nucleotide excision repair (NER) mechanism. A new trial is evaluating if the status of ERCC5 (XPG), an endonuclease-3 that plays a key role in the excision of damaged DNA, is linked to trabectedin's clinical activity in patients with advanced soft tissue sarcoma.

New data suggests that overexpression of the wild-type ERCC5 gene may be a predictor of beneficial effects of trabectedin in patients with advanced STS.

A second trial is analyzing in vitro and in vivo activity of trabectedin in a group of 67 human tumors with a view to identify a common genetic profile and pinpoint Yondelis(R)-sensitive tumors. The results of this analysis demonstrate the viability of combining experimental trials with virtual prediction to identify other tumors that are potential candidates for new preclinical and clinical trials with the compound. Phase II clinical trials are currently under way with Yondelis(R) in breast, lung and prostate cancers and pediatric tumors.

Three other trials presented at the AACR meeting provided new data on Irvalec(R), a novel marine-based synthetic depsipeptide currently in Phase II trials for lung cancer.

The first trial is evaluating the modulation of initial cytotoxic effects of Irvalec(R) using zinc and DIDS in lung cancer cells. The results suggest that plasma membrane damage caused by Irvalec(R) generates a rapid onset of hydroelectrolyte imbalance, causing severe alterations that lead to cell death by necrosis.

A second trial sheds light on the molecular mechanism associated with sensitivity and resistance to Irvalec(R). Conclusions show that primary and acquired resistance to Irvalec(R) may be associated with the expression of ErbB receptors and epithelial mesenchymaltransition markers.

A third trial shows that overexpression of ErbB2 and ErbB3 receptors does not affect sensitivity to Irvalec(R), although the receptors do suffer some changes as a result of alterations in the cell membrane produced by the compound.

Another trial suggests that PDGFRA could be a useful predictive biomarker of response to Zalypsis(R), a novel chemical entity related to the marine natural compounds jorumycin and the renieramycin family, obtained from mollusks and sponges. Zalypsis(R) is currently in Phase II trials for endometrial and cervical cancer.

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis(R) is Spain's first anti-cancer drug. It is currently approved for STS in 25 countries outside the EEA, and in five of those countries for platinum-sensitive ROC as well. Yondelis(R) is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis(R) are also under way on prostate, breast, lung and pediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin(R), Irvalec(R), Zalypsis(R) and PM01183. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D program.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

This press release is also available in the "News" section of the PharmaMar Web site: www.pharmamar.com


'/>"/>
SOURCE PharmaMar
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
3. Limbs for Life Foundation Presents the Roaring 20s at 9th Annual Benefit Gala and Auction
4. The Womens Heart Foundation Presents the Womens Heart Advocate Award for Medicine and Science to Multifunction CardioGram(TM) Inventor Dr. Joseph T. Shen
5. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
6. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
7. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
8. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
9. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
10. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
11. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute lymphocytic Leukemia Market and ... their offering.       (Logo: ... Lymphocytic Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Lymphocytic Leukemia epidemiology, ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... to further expand product development, strengthen its disease modeling capabilities and increase market presence. Photo - ... ... ... ... Sino-German High-Tech Fund (SGHF) is an ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate ... weather is too cold, dry or hot, water on the eye surface can evaporate, ... from the surrounding air. There’s only one problem, according to radio show and water ...
(Date:5/6/2016)... ... May 06, 2016 , ... The International Yoga Teacher Training schoo ... of the island close to the town famous for its sunsets, Oia. This all ... “We continue to have an amazing experience in Greece, we just can’t stay away” ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of Military ... corporate training, and the National Military Family Association, a nonprofit that works to ... second full-tuition scholarship recipient of 2016. , “Being awarded this scholarship by ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TransWipe Volume 3 ... Pro X. Drag and drop a TransWipe preset between two video clips to instantly ... corner wipes to colored panels with customizable color and orientation options. TransWipe Volume 3 ...
(Date:5/5/2016)... Chicago, Illinois (PRWEB) , ... May 05, 2016 ... ... published its “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit ... as a “tobacco product,” apply to all vaping products that entered the market ...
Breaking Medicine News(10 mins):